Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Numinus Wellness Focused on Boosting Profitability and Expanding Community Support (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Instil Bio Inc TIL

Healthcare Biotechnology
Instil Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. The Company seeks to in-license/acquire and develop novel therapeutic candidates in diseases with significant unmet medical need. Its first such program is an engineered tumor infiltrating lymphocyte (TIL), cell therapy for the treatment of cancer. It is engaged in developing a... see more

Recent & Breaking News (NDAQ:TIL)

Instil Bio to Present Novel TIL Analytics at American Society of Gene and Cell Therapy (ASGCT)

GlobeNewswire May 18, 2022

Instil Bio Reports First Quarter 2022 Financial Results and Provides Corporate Update

GlobeNewswire May 16, 2022

Instil Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

GlobeNewswire March 7, 2022

Instil Bio to Present at the Cowen 42nd Annual Health Care Conference

GlobeNewswire March 2, 2022

Instil Bio Reports Third Quarter 2021 Financial Results and Provides Corporate Update

GlobeNewswire November 15, 2021

Instil Bio Announces Poster Presentations at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting

GlobeNewswire November 15, 2021

Instil Bio to Present at Upcoming Investor Conferences in November

GlobeNewswire November 8, 2021

Instil Bio Presents Subset Analysis of Patients with Checkpoint-Refractory Advanced Melanoma from Compassionate Use Study at 2021 ESMO Congress

GlobeNewswire September 16, 2021

Instil Bio Receives IND Clearance to Initiate a Phase 2 Clinical Trial for Patients with Advanced Melanoma

GlobeNewswire September 13, 2021

Instil Bio to Present at Upcoming Investor Conferences in September

GlobeNewswire September 2, 2021

Instil Bio Reports Second Quarter 2021 Financial Results and Provides Corporate Update

GlobeNewswire August 12, 2021

IIROC Trading Resumption - TIL

Canada NewsWire June 21, 2021

IIROC Trading Halt - TIL

Canada NewsWire June 21, 2021

Instil Bio to Present at the Jefferies Virtual Healthcare Conference

GlobeNewswire June 1, 2021

Instil Bio Reports First Quarter 2021 Financial Results and Provides Corporate Update

GlobeNewswire May 13, 2021

Instil Bio Receives Orphan Drug Designation for ITIL-168 in Melanoma

GlobeNewswire April 27, 2021

Instil Bio Presents Clinical Data in Metastatic Melanoma in a Late-Breaking e-Poster at the 2021 American Association for Cancer Research (AACR) Annual Meeting

GlobeNewswire April 12, 2021

Instil Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewswire March 23, 2021

Instil Bio Announces Pricing of Upsized Initial Public Offering

GlobeNewswire March 18, 2021

IIROC Trading Resumption - TIL

Canada NewsWire December 2, 2019